Literature DB >> 15951244

Assessment of blinding may be inappropriate after the trial.

Harri Hemilä.   

Abstract

Mesh:

Year:  2005        PMID: 15951244     DOI: 10.1016/j.cct.2005.04.002

Source DB:  PubMed          Journal:  Contemp Clin Trials        ISSN: 1551-7144            Impact factor:   2.226


× No keyword cloud information.
  6 in total

1.  Use of dose modification schedules is effective for blinding trials of warfarin: evidence from the WASID study.

Authors:  Vicki Hertzberg; Marc Chimowitz; Michael Lynn; Cristen Chester; William Asbury; George Cotsonis
Journal:  Clin Trials       Date:  2008       Impact factor: 2.486

Review 2.  Towards a proposal for assessment of blinding success in clinical trials: up-to-date review.

Authors:  Jafar Kolahi; Heejung Bang; Jongbae Park
Journal:  Community Dent Oral Epidemiol       Date:  2009-09-15       Impact factor: 3.383

3.  A new framework for interpreting the outcomes of imperfectly blinded controlled clinical trials.

Authors:  Ognjen Arandjelović
Journal:  PLoS One       Date:  2012-12-06       Impact factor: 3.240

4.  Clinical Trial Adaptation by Matching Evidence in Complementary Patient Sub-groups of Auxiliary Blinding Questionnaire Responses.

Authors:  Ognjen Arandjelović
Journal:  PLoS One       Date:  2015-07-10       Impact factor: 3.240

Review 5.  Maintenance of Blinding in Clinical Trials and the Implications for Studying Analgesia Using Cannabinoids.

Authors:  Barth Wilsey; Reena Deutsch; Thomas D Marcotte
Journal:  Cannabis Cannabinoid Res       Date:  2016-07-01

Review 6.  Bias against Vitamin C in Mainstream Medicine: Examples from Trials of Vitamin C for Infections.

Authors:  Harri Hemilä; Elizabeth Chalker
Journal:  Life (Basel)       Date:  2022-01-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.